

Clinical trials of insulin sensitizer for diabetes type 2 in all type of patients

TrialResults-center www.trialresultscenter.org

1 biguanide

Trial	Treatments	Patients	Trials design and methods
metformin vs Acarbose			
Maji vs acarbose n=48/48 follow-up: 156	500 versus Acarbose	-	
metformin vs Glibenclamide			
Yki-Yarvinen vs glibenclamide , 1999 n=19/22 follow-up: 52	2.000 versus Glibenclamide	-	
Kahn (ADOPT) vs glibenclamide n=1454/1441 follow-up: 208	2.000 versus Glibenclamide	-	
metformin vs Glimepiride			
Yamanouchi vs glimepiride , 2005 n=39/37 follow-up: 52	750 versus Glimepiride	-	
metformin vs Glipizide/			
Vahatalo vs glipizide/glimepiride n=26/15 follow-up: 52	2.500- versus Glipizide/	-	
metformin vs Insulin			
Yki-Yarvinen vsinsulin n=19/24 follow-up: 52	2.000 versus Insulin	-	
Klein , 1991 n=25/25 follow-up: 52	2.550 versus Insulin	-	
Barnett , 2008 n=211/235 follow-up: 128	NR versus Insulin	-	
metformin vs None			
Vahatalo vs control , 2007 n=26/11 follow-up: 52	2.500 versus None	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Maji vs control , 2005 n=48/90 follow-up: 156	500 versus None	-	
UKPDS 34 vs control n=342/411 follow-up: 556	2.550 versus None	-	
UKPDS 34 bis n=268/269 follow-up: 343	2.550 versus None	-	
Zhang n=49/45 follow-up: 76	750 versus None	-	
Ramachandran n=262/269 follow-up: 156	500 versus None	-	
metformin vs Pioglitazone			
Yamanouchi vs pioglitazone n=39/38 follow-up: 52	750 versus Pioglitazone	-	
Shernthaner , 2004 n=597/597 follow-up: 52	2.000 versus Pioglitazone	-	
Derosa , 2009 n=67/69 follow-up: 64	3.000 versus Pioglitazone	-	
Charbonnel , 2005 n=320/319 follow-up: 104	2.550 versus Pioglitazone	-	
metformin vs placebo			
Hermann , 2001 n=16/19 follow-up: 52 weeks	metformin 65279;1.700 versus Placebo	obese and overweight type 2 diabetes patients treated with insulin for at least 1 year, and with poor glycaemic control (HbA1c >upper reference level + 2%)	Parallel groups double-blind
Douek , 2005 n=92/91 follow-up: 52	2.000 versus Placebo	-	
Gregorio , 1999 n=89/85 follow-up: 76	1.700 versus Placebo	-	
Teupe , 1991 n=50/50 follow-up: 104	1.700 versus Placebo	Type 2 diabetic patients	Parallel groups open Canada

continued...

Trial	Treatments	Patients	Trials design and methods
Kooy (HOME) , 2009 n=196/194 follow-up: 220	2.000 versus Placebo	Patients with type 2 diabetes	Parallel groups double blind
palomba n=15/15 follow-up: 52	1.700 versus Placebo	-	
Ibanez n=12/12 follow-up: 52	850 versus Placebo	-	
Harborne n=26/26 follow-up: 52	1.500 versus Placebo	-	
Li n=33/37 follow-up: 52	2.000 versus Placebo	-	
Martinez n=35/73 follow-up: 52	1.700 versus Placebo	-	
Gambineri n=40/40 follow-up: 52	1.700 versus Placebo	-	
Lund n=49/51 follow-up: 52	2.000 versus Placebo	-	
BIGPRO (Charles) n=164/160 follow-up: 52	1.700 versus Placebo	-	
Stakos vs placebo n=59/97 follow-up: 104	500 versus Placebo	-	
Shuster n=45/81 follow-up: 104	500 versus Placebo	-	
DPP (Knowler) n=1073/1082 follow-up: 156	1.700 versus Placebo	-	
Ibanez 62 n=19/19 follow-up: 208	425 versus Placebo	-	
metformin vs Rosiglitazone			
maji vs rosiglitazone n=48/48 follow-up: 156	500 versus Rosiglitazone	-	

continued...

Trial	Treatments	Patients	Trials design and methods
ADOPT vs rosiglitazone n=1454/1456 follow-up: 208	2.000 versus Rosiglitazone	-	
RECORD n=1122/1103 follow-up: 260	2.550 versus Rosiglitazone	-	
Tomazic n=30/30 follow-up: 52	1.000 versus Rosiglitazone	-	
metformin vs Vildagliptin			
Schweizer , 2007 n=254/526 follow-up: 52	2.000 versus Vildagliptin	-	
metformin vs Glipizide			
Campbell , 1994 n=24/24 follow-up: 52	1.000 versus Glipizide	-	
Stakos vs glipizide n=59/25 follow-up: 104	500 versus Glipizide	-	
metformin vs SU/Insulin			
UKPDS (vs SU or INS) n=342/951 follow-up: 556	2.550 versus SU/Insulin	Type 2 diabetic patients	Parallel groups open UK

References

Maji vs acarbose, :

Yki-Yarvinen vs glibenclamide, 1999:

Yki-Jrvinen H, Ryysy L, Nikkil K, Tulokas T, Vanamo R, Heikkil M Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 1999;130:389-96 [[10068412](#)]

Kahn (ADOPT) vs glibenclamide, :

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355:2427-43 [[17145742](#)] [10.1056/NEJMoa066224](#)

Yamanouchi vs glimepiride, 2005:

Yamanouchi T, Sakai T, Igarashi K, Ichiyanaagi K, Watanabe H, Kawasaki T Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. *Diabet Med* 2005;22:980-5 [[16026361](#)] [10.1111/j.1464-5491.2005.01656.x](#)

Vahatalo vs glipizide/glimepiride, :

Yki-Yarvinen vs insulin, :

Klein, 1991:

Klein W Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. *Diabete Metab* 1991;17:235-40 [[1936483](#)]

Barnett, 2008:

Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. *Int J Clin Pract* 2007;61:1614-25 [[17877648](#)] [10.1111/j.1742-1241.2007.01522.x](#)

Vahatalo vs control, 2007:

Vhtalo M, Rnnema T, Viikari J Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. *Scand J Prim Health Care* 2007;25:147-53 [[17846932](#)] [10.1080/02813430701507719](#)

Maji vs control, 2005:

Maji D, Roy RU, Das S Prevention of type 2 diabetes in the prediabetic population. *J Indian Med Assoc* 2005;103:609-11 [[16570766](#)]

UKPDS 34 vs control, :**UKPDS 34 bis, :****Zhang, :**

Zhang JL, Zheng X, Zou DJ, Qiu JL, Zhao XX, Qin YW Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. *Am J Hypertens* 2009;22:884-90 [[19574961](#)] [10.1038/ajh.2009.93](#)

Ramachandran, :

Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006;49:289-97 [[16391903](#)] [10.1007/s00125-005-0097-z](#)

Yamanouchi vs pioglitazone, 0:**Shernthaner, 2004:**

Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. *J Clin Endocrinol Metab* 2004;89:6068-76 [[15579760](#)] [10.1210/jc.2003-030861](#)

Derosa, 2009:

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. *Metabolism* 2009;58:1059-66 [[19394976](#)] [10.1016/j.metabol.2009.03.007](#)

Charbonnel, 2005:

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. *Diabetologia* 2005;48:1093-104 [[15889234](#)] [10.1007/s00125-005-1751-1](#)

Hermann, 2001:

Hermann LS, Kaln J, Katzman P, Lager I, Nilsson A, Norrhamn O, Sartor G, Ugander L Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. *Diabetes Obes Metab* 2001;3:428-34 [[11903415](#)]

Douek, 2005:

Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. *Diabet Med* 2005;22:634-40 [[15842521](#)] [10.1111/j.1464-5491.2005.01475.x](#)

Gregorio, 1999:

Gregorio F, Ambrosi F, Manfrini S, Velussi M, Carle F, Testa R, Merante D, Filippini P Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. *Diabet Med* 1999;16:1016-24 [[10656230](#)]

Teupe, 1991:

Teupe B, Bergis K Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. *Diabete Metab* 1991;17:213-7 [[1936479](#)]

Kooy (HOME), 2009:

Kooy A, de Jager J, Lehert P, Bets D, Wulfel MG, Donker AJ, Stehouwer CD Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. *Arch Intern Med* 2009;169:616-25 [[19307526](#)]

palomba, :

Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, De Feo P, Orio F Jr Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2007;92:3128-35 [[17519312](#)] [10.1210/jc.2007-0441](#)

Ibanez, :

Ibez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. *J Pediatr* 2004;144:23-9 [[14722514](#)] [10.1016/j.jpeds.2003.08.015](#)

Harborne, :

Harborne L, Fleming R, Lyall H, Sattar N, Norman J Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:4116-23 [[12970273](#)]

Li, :

Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, Xia FC, Wang HZ, Wang HY Effect of metformin on patients with impaired glucose tolerance. *Diabet Med* 1999;16:477-81 [[10391395](#)]

Martinez, :

Martnez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, Prez-Cuevas JB, Casamitjana R, de Lazzari E, Bianchi L, Montserrat E, Roca M, Burgos R, Arnaiz JA, Gatell JM Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. *Antivir Ther* 2003;8:403-10 [[14640387](#)]

Gambineri, :

Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. *J Clin Endocrinol Metab* 2006;91:3970-80 [[16868063](#)] [10.1210/jc.2005-2250](#)

Lund, :

Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. *PLoS One* 2008;3:e3363 [[18852875](#)] [10.1371/journal.pone.0003363](#)

BIGPRO (Charles), :

Charles MA, Morange P, Eschwge E, Andr P, Vague P, Juhan-Vague I Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. *Diabetes Care* 1998;21:1967-72 [[9802752](#)]

Stakos vs placebo, :**Shuster, :**

Schuster D, Gaillard T, Rhinesmith S, Habash D, Osei K Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study. *Diabetes Care* 2004;27:2768-9 [[15505024](#)]

DPP (Knowler), :**Ibanez 62, 0:**

Ibez L, Lopez-Bermejo A, Daz M, Marcos MV, de Zegher F Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. *J Clin Endocrinol Metab* 2008;93:1841-5 [[18319306](#)] [10.1210/jc.2008-0013](#)

maji vs rosiglitazone, :**ADOPT vs rosiglitazone, :****RECORD, :****Tomazic, :**

Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. *Acta Dermatovenerol Alp Panonica Adriat* 2005;14:99-105 [[16200335](#)]

Schweizer, 2007:

Schweizer A, Couturier A, Foley JE, Dejager S Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007;24:955-61 [[17509069](#)] [10.1111/j.1464-5491.2007.02191.x](#)

Campbell, 1994:

Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994;20:394-400 [[7843470](#)]

Stakos vs glipizide, :

Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005;91:589-94 [[15831640](#)] [10.1136/hrt.2003.027722](#)

UKPDS (vs SU or INS), 0:

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65 [[9742977](#)]

2 PPAR modulator

Trial	Treatments	Patients	Trials design and methods
tesaglitazar vs			
GALLANT 9 [NCT00242372] n=NA	-	-	
GALLANT 7 [NCT00251940] n=NA	-	-	
GALLANT 8 [NCT00251953] n=NA	-	-	
GALLANT 6 [NCT00214565] n=NA	-	-	
D6160C00028 [NCT00255541] n=NA	-	-	
D6160C00026 [NCT00252772] n=NA	-	-	
GALLANT 14 [NCT00261352] n=NA	-	-	
D6160C00055 [NCT00252837] n=NA	-	-	
D6160C00040 [NCT00229684] n=NA	-	-	

continued...

Trial	Treatments	Patients	Trials design and methods
aleglitazar vs actos			
BC20265 <i>ongoing</i> [NCT00461058] n=NA follow-up:	aleglitazar versus Actos(r)	-	USA
aleglitazar vs placebo			
ALECARDIO [NCT01042769] n=NA	-	-	
BC22140 <i>ongoing</i> [NCT01042769] n=NA follow-up: 2.5 years	aleglitazar on top of standard care versus placebo	patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus	double-blind USA

References

GALLANT 9, :
 GALLANT 7, :
 GALLANT 8, :
 GALLANT 6, :
 D6160C00028, :
 D6160C00026, :
 GALLANT 14, :
 D6160C00055, :
 D6160C00040, :
 BC20265, 0:
 ALECARDIO, :
 BC22140, 0:

3 thiazolidinediones

Trial	Treatments	Patients	Trials design and methods
vs			
Bailey , 2005 n=NA	-	-	
EMPIRE (Weissman) , 2005 n=NA	-	-	
Hallsten , 2002 n=NA	-	-	
Hanefeld , 2004 n=NA	-	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Lawrence , 2004 n=NA	-	-	
Pavo , 2003 n=NA	-	-	
Ramachandran , 2004 n=NA	-	-	
Scherthamer , 2004 n=NA	-	-	
Yamanouchi , 2005 n=NA	-	-	
rosiglitazone vs			
AVM100264 [NCT00359112] n=294/302 follow-up: 52 wk	Rosiglitazone and metformin versus Metformin and sulfonylurea	Overweight patients with type 2 DM poorly controlled on Met	Parallel groups
BRL 49653C/185 n=563/142 follow-up: 32 wk	Rosiglitazone with or without metformin versus Usual care with or without metformin	patients with type 2 diabetes	Parallel groups
SB-712753/007 n=314/154 follow-up: 32 wk	Rosiglitazone with or without metformin versus Metformin	patients with type 2 diabetes without previous drug therapy	Parallel groups
SB-712753/009 n=162/160 follow-up: 24 wk	Rosiglitazone, metformin, and insulin versus Insulin	patients with type 2 diabetes with insulin	Parallel groups
rosiglitazone vs control			
Wang , 2005 n=NA follow-up: 6 months	rosiglitazone 4 mg/d versus control	patients with diabetes and CAD who had undergone percutaneous coronary intervention	Parallel groups open
vs DPP-4 inhibitor (add on to metformin)			
Scott (vs DPP-4 inhibitor) , 2008 n=87/94 follow-up: 18 weeks	-	-	
rosiglitazone vs glyburide			
49653/020 n=391/207 follow-up: 52 wk	Rosiglitazone versus Glyburide	patients with type 2 diabetes	Parallel groups
49653/079 n=203/106 follow-up: 26 wk	Rosiglitazone with or without glyburide versus Glyburide	patients with type 2 diabetes poorly controlled on maximum dose of Gly	Parallel groups
49653/080 n=104/99 follow-up: 156 wk	Rosiglitazone versus Glyburide	patients with type 2 diabetes	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
49653/097 n=122/120 follow-up: 156 wk	Rosiglitazone versus Glyburide	patients with type 2 diabetesDM	Parallel groups
49653/143 [NCT00333723] n=121/124 follow-up: 24 wk	Rosiglitazone and glyburide versus Glyburide	Type 2 DM poorly controlled on glyburide	Parallel groups
rosiglitazone vs glyburide (add on MET)			
49653/137 [NCT00500955] n=204/185 follow-up: 32 wk	Rosiglitazone and metformin versus Glyburide and metformin	patients with type 2 diabetes	Parallel groups
pioglitazone vs metformin			
EC404 n=597/597 follow-up: 52 wk	Pioglitazone versus Metformin	patients with type 2 diabetes	Parallel groups
rosiglitazone vs metformin			
49653/093 n=213/109 follow-up: 26 wk	Rosiglitazone with or without metformin versus Metformin	patients with type 2 diabetes poorly controlled on Met	Parallel groups
49653/094 n=232/116 follow-up: 26 wk	Rosiglitazone and metformin versus Metformin	Type 2 DM poorly controlled on Met	Parallel groups
pioglitazone + sulfonylurea vs metformin + sulfonylurea			
EC409 n=319/320 follow-up: 104 wk	Pioglitazone + sulfonylurea versus Metformin + sulfonylurea	patients with type 2 diabetes	Parallel groups
pioglitazone vs placebo			
PNFP-001 n=329/79 follow-up: 26 wk	Pioglitazone versus Placebo	patients with type 2 diabetes	Parallel groups
PNFP-012 n=176/84 follow-up: 24 wk	Pioglitazone versus Placebo	patients with type 2 diabetes	Parallel groups
PNFP-026 n=101/96 follow-up: 16 wk	Pioglitazone versus Placebo	patients with type 2 diabetes	Parallel groups
PROactive , 2005 [NCT00174993] n=2605/2633 follow-up: 34.5 mo	pioglitazone titrated from 15 mg to 45 mg versus placebo	Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease	Parallel groups double blind 19 European countries
rosiglitazone vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
49653/011 n=357/176 follow-up: 24 wk	Rosiglitazone versus Placebo	patients with type 2 diabetes	Parallel groups
49653/128 n=39/38 follow-up: 28 wk	Rosiglitazone versus Placebo	patients with type 2 diabetes on concurrent Su	Parallel groups
49653/134 n=561/276 follow-up: 28 wk	Rosiglitazone versus Placebo	patients with type 2 diabetes on Gly and Met	Parallel groups
49653/136 n=148/143 follow-up: 26 wk	Rosiglitazone versus Placebo	patients with type 2 diabetes and chronic renal failure on Su, insulin, or both	Parallel groups
49653/330 n=1/382 follow-up: 52 wk	Rosiglitazone versus Placebo	Chronic psoriasis	Parallel groups
49653/331 n=706/325 follow-up: 52 wk	Rosiglitazone versus Placebo	Chronic psoriasis	Parallel groups
AVA100193 n=394/124 follow-up: 24 wk	Rosiglitazone versus Placebo	Mild-to-moderate Alzheimers disease	Parallel groups
BRL 49653/334 [NCT00306644] n=278/279 follow-up: 52 wk	Rosiglitazone versus Placebo	patients with type 2 diabetes or insulin resistance syndrome	Parallel groups
rosiglitazone pioglitazone vs placebo			
TIDE <i>ongoing</i> [NCT00879970] n=16000 follow-up:	pioglitazone or rosiglitazone versus placebo	patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease	Factorial plan double-blind USA
rosiglitazone vs placebo (add on gliclazide)			
49653/145 n=231/242 follow-up: 26 wk	Rosiglitazone and gliclazide versus Gliclazide	patients with type 2 diabetes	Parallel groups
rosiglitazone vs placebo (add on glimepiride)			
49653/234 n=116/61 follow-up: 26 wk	Rosiglitazone and glimepiride versus Glimepiride	patients with type 2 diabetes	Parallel groups
rosiglitazone vs placebo (add on glipizide)			
49653/135 n=116/111 follow-up: 104 wk	Rosiglitazone and glipizide versus Glipizide	Elderly patients with type 2 DM	Parallel groups
rosiglitazone vs placebo (add on glyburide)			

continued...

Trial	Treatments	Patients	Trials design and methods
100684 [NCT01045590] n=43/47 follow-up: 52 wk	Rosiglitazone and glyburide versus Glyburide	Korean patients with type 2 DM	Parallel groups
49653/127 n=56/58 follow-up: 26 wk	Rosiglitazone and glyburide versus Glyburide	patients with type 2 diabetes poorly controlled on Gly	Parallel groups
49653/162 n=168/172 follow-up: 26 wk	Rosiglitazone and glyburide versus Glyburide	patients with type 2 diabetes	Parallel groups
pioglitazone + insulin vs placebo (add on insulin)			
OPI-502 n=110/112 follow-up: 20 wk	Pioglitazone + insulin versus Placebo + insulin	Insulin-dependent DM-2	Parallel groups
PNFP-014 n=379/187 follow-up: 16 wk	Pioglitazone insulin versus Placebo + insulin	patients with type 2 diabetes	Parallel groups
rosiglitazone vs placebo (add on insulin)			
49653/085 n=138/139 follow-up: 26 wk	Rosiglitazone and insulin versus Insulin	patients with type 2 diabetes	Parallel groups
49653/095 n=196/96 follow-up: 26 wk	Rosiglitazone and insulin versus Insulin	patients with type 2 diabetes poorly controlled on insulin	Parallel groups
BRL 49653/347 [NCT00054782] n=418/212 follow-up: 24 wk	Rosiglitazone and insulin versus Insulin	patients with type 2 diabetes poorly controlled on insulin	Parallel groups
vs placebo (add on MET)			
Fonseca , 2000 n=113/116 follow-up: 26 weeks	-	-	
Gomez-Perez , 2002 n=36/34 follow-up: 26 weeks	-	-	
scott , 2008 n=87/91 follow-up: 18 weeks	-	-	
pioglitazone + metformin vs placebo (add on MET)			
PNFP-027 n=168/160 follow-up: 16 wk	Pioglitazone + metformin versus Placebo +metformin	patients with type 2 diabetes	Parallel groups
rosiglitazone vs placebo (add on MET)			

continued...

Trial	Treatments	Patients	Trials design and methods
49653/284 [NCT00501020] n=382/384 follow-up: 24 wk	Rosiglitazone and metformin versus Metformin	patients with type 2 diabetes	Parallel groups
712753/008 [NCT00241605] n=284/135 follow-up: 48 wk	Rosiglitazone and metformin versus Metformin	Type 2 DM poorly controlled on Met	Parallel groups
SB-712753/002 n=288/280 follow-up: 24 wk	Rosiglitazone and metformin versus Metformin	patients with type 2 diabetes poorly controlled	Parallel groups
SB-712753/003 n=254/272 follow-up: 32 wk	Rosiglitazone and metformin versus Metformin	Mild type 2 DM	Parallel groups
rosiglitazone vs placebo (add on SU)			
49653/015 n=395/198 follow-up: 24 wk	Rosiglitazone and sulfonylurea versus Sulfonylurea	patients with type 2 diabetes	Parallel groups
49653/125 [NCT00422955] n=175/173 follow-up: 26 wk	Rosiglitazone and sulfonylurea versus Sulfonylurea	patients with type 2 diabetes	Parallel groups
49653/132 n=442/112 follow-up: 24 wk	Rosiglitazone and sulfonylurea versus Sulfonylurea	Patients in China with type 2 DM	Parallel groups
49653/147 n=89/88 follow-up: 26 wk	Rosiglitazone and sulfonylurea versus Sulfonylurea	Indo-Asian patients with type 2 diabetes	Parallel groups
pioglitazone vs rosiglitazone			
GLAI [NCT00331487] n=369/366 follow-up: 24 wk	Pioglitazone versus Rosiglitazone	patients with type 2 diabetes and dyslipidemia	Parallel groups
pioglitazone vs standard glucose-lowering drugs			
PPAR <i>ongoing</i> [NCT00212004] n=NA follow-up:	pioglitazone versus sulfonylurea agents	diabetes patients with a history of prior myocardial infarction	Parallel groups Japan
pioglitazone vs sulfonylurea			
EC405 n=624/626 follow-up: 52 wk	Pioglitazone versus Sulfonylurea	patients with type 2 diabetes	Parallel groups
OPI-501 n=251/251 follow-up: 56 wk	Pioglitazone versus Sulfonylurea	Recently diagnosed DM-2	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
OPI-504 [NCT00521820] n=262/256 follow-up: 24 wk	Pioglitazone versus Sulfonylurea	patients with type 2 diabetes and mild to moderate congestive heart failure	Parallel groups
OPI-506 [NCT00494312] n=1051/1046 follow-up: 156 wk	Pioglitazone versus Sulfonylurea	Inadequately controlled DM-2	Parallel groups
OPI-520 [NCT00521742] n=151/149 follow-up: 52 wk	Pioglitazone versus Sulfonylurea	Inadequately controlled DM-2 with mild cardiac disease (New York Heart Association Class I)	Parallel groups
pioglitazone + sulfonylurea vs sulfonylurea			
PNFP-010 n=373/187 follow-up: 16 wk	Pioglitazone + sulfonylurea versus Sulfonylurea	patients with type 2 diabetes	Parallel groups
vs sulfonylurea (add on to MET)			
Garber , 2006 n=155/159 follow-up: 24 weeks	-	-	
Hamann , 2008 n=294/301 follow-up: 52 weeks	-	-	
Khanolkar , 2008 n=25/25 follow-up: 24 weeks	-	-	
Matthews , 2005 n=317/313 follow-up: 52 weeks	-	-	
pioglitazone + metformin vs sulfonylurea + metformin			
EC410 n=317/313 follow-up: 104 wk	Pioglitazone + metformin versus Sulfonylurea + metformin	patients with type 2 diabetes	Parallel groups
rosiglitazone vs usual care			
49653/211 n=110/114 follow-up: 52 wk	Rosiglitazone and usual care versus Usual care	Type 2 DM with CHF	Parallel groups
pioglitazone vs vildagliptin			
Bolli , 2008 n=295/295 follow-up: 52 weeks	vildagliptin (50 mg b.i.d.) versus pioglitazone (30 mg daily)	-	
pioglitazone vs glimepiride			

continued...

Trial	Treatments	Patients	Trials design and methods
PERISCOPE , 2008 [NCT00225277] n=274/273 follow-up: 18 months	pioglitazone 15 to 45 mg versus glimepiride, 1 to 4 mg	patients with coronary disease and type 2 diabetes	Parallel groups double blind North and South America
rosiglitazone vs glipizide			
APPROACH , 2008 [NCT00116831] n=333/339 follow-up: 18 months	rosiglitazone at up to 8 mg/day versus glipizide at 15 mg/day	patients with type 2 diabetes and coronary artery disease	Parallel groups double blind
rosiglitazone vs standard glucose-lowering drugs			
ADOPT , 2006 [NCT00279045] n=1456/2895 follow-up: 4y (median)	Rosiglitazone 4mg twice daily versus Metformin 1000mg twice daily or glyburide 7.5mg twice daily	Recently diagnosed type type 2 diabetes	Parallel groups double blind United States, Canada, Europe
RECORD , 2009 [NCT00379769] n=2220/2227 follow-up: 5.5 y	addition of rosiglitazone (4-8 mg daily titrated) to metformin or sulfonylurea, target HbA1c<=70% versus combination of metformin and sulfonylurea, target HbA1c<=70%	patients with type 2 diabetes onmonotherapy with either metformin or sulfonylurea andin less than optimal blood glucose control (HbA1c >7090%)	Parallel groups open Europe, Australia

References

Bailey, 2005:

Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. *Clin Ther* 2005;27:1548-61 [16330291] [10.1016/j.clinthera.2005.10.012](https://doi.org/10.1016/j.clinthera.2005.10.012)

EMPIRE (Weissman), 2005:

Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. *Curr Med Res Opin* 2005;21:2029-35 [16368054] [10.1185/030079905X74844](https://doi.org/10.1185/030079905X74844)

Hallsten, 2002:

Hllsten K, Virtanen KA, Lnnqvist F, Sipil H, Oksanen A, Viljanen T, Rnnemaa T, Viikari J, Knuti J, Nuutila P Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. *Diabetes* 2002;51:3479-85 [12453903]

Hanefeld, 2004:

Hanefeld M, Brunetti P, Scherthaner GH, Matthews DR, Charbonnel BH One-year glyceic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. *Diabetes Care* 2004;27:141-7 [14693980]

Lawrence, 2004:

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. *Diabetes Care* 2004;27:41-6 [14693964]

Pavo, 2003:

Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH Effect of pioglitazone compared with metformin on glyceic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. *J Clin Endocrinol Metab* 2003;88:1637-45 [12679450]

Ramachandran, 2004:

Ramachandran A, Snehalatha C, Salini J, Vijay V Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes—a study in Indians. *J Assoc Physicians India* 2004;52:459-63 [15645955]

Schernthaner, 2004:

Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. *J Clin Endocrinol Metab* 2004;89:6068-76 [15579760] [10.1210/jc.2003-030861](#)

Yamanouchi, 2005:

Yamanouchi T, Sakai T, Igarashi K, Ichiyangi K, Watanabe H, Kawasaki T Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. *Diabet Med* 2005;22:980-5 [16026361] [10.1111/j.1464-5491.2005.01656.x](#)

AVM100264 , :

BRL 49653C/185 , :

SB-712753/007 , :

SB-712753/009 , :

Wang, 2005:

Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X, Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. *Metabolism* 2005;54:590-7. [15877288] [10.1016/j.metabol.2004.11.017](#)

Scott (vs DPP-4 inhibitor), 2008:

49653/020 , :

49653/079 , :

49653/080 , :

49653/097 , :

49653/143 , :

49653/137 , :

EC404, :

49653/093 , :

49653/094 , :

EC409, :

PNFP-001, :

PNFP-012, :

PNFP-026, :

PROactive, 2005:

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Po Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005 Oct 8;366:1279-89 [16214598]

49653/011 , :

49653/128 , :

49653/134 , :

49653/136 , :

49653/330 , :

49653/331 , :

AVA100193 , :

BRL 49653/334 , :

TIDE, :

49653/145 , :

49653/234 , :
49653/135 , :
100684 , :
49653/127 , :
49653/162 , :
OPI-502, :
PNFP-014, :
49653/085 , :
49653/095 , :
BRL 49653/347 , :
Fonseca, 2000:

Fonseca V, Rosenstock J, Patwardhan R, Salzman A Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702 [[10755495](#)]

Gomez-Perez, 2002:

Gomez-Perez FJ, Fanghnel-Salmon G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, Gould EM Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34 [[11994904](#)] [10.1002/dmrr.264](#)

scott, 2008:

Scott R, Loeyes T, Davies MJ, Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69 [[18201203](#)] [10.1111/j.1463-1326.2007.00839.x](#)

PNFP-027, :

49653/284 , :

712753/008 , :

SB-712753/002 , :

SB-712753/003 , :

49653/015 , :

49653/125 , :

49653/132 , :

49653/147 , :

GLAI, :

PPAR, :

EC405, :

OPI-501, :

OPI-504, :

OPI-506, 0:

OPI-520, :

PNFP-010, :

Garber, 2006:

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8:156-63 [[16448519](#)] [10.1111/j.1463-1326.2005.00570.x](#)

Hamann, 2008:

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. *Exp Clin Endocrinol Diabetes* 2008;116:6-13 [18095238] [10.1055/s-2007-984441](https://doi.org/10.1055/s-2007-984441)

Khanolkar, 2008:

Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—an effect probably mediated by direct platelet PPARgamma activation. *Atherosclerosis* 2008;197:718-24 [17765245] [10.1016/j.atherosclerosis.2007.07.020](https://doi.org/10.1016/j.atherosclerosis.2007.07.020)

Matthews, 2005:

Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Scherthaner G Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. *Diabetes Metab Res Rev* 2005;21:167-74 [15386821] [10.1002/dmrr.478](https://doi.org/10.1002/dmrr.478)

EC410, :

49653/211 , :

Bolli, 2008:

Bolli G, Dotta F, Rochotte E, Cohen SE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 2008;10:82-90 [18034842] [10.1111/j.1463-1326.2007.00820.x](https://doi.org/10.1111/j.1463-1326.2007.00820.x)

Bolli G, Dotta F, Colin L, Minic B, Goodman M Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab* 2009;11:589-95 [19515179] [10.1111/j.1463-1326.2008.01023.x](https://doi.org/10.1111/j.1463-1326.2008.01023.x)

PERISCOPE, 2008:

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Laroche R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008 Apr 2;299:1561-73 [18378631]

Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, Kupfer S, Perez A, Nesto R, Nissen SE Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. *J Am Coll Cardiol* 2011;57:153-9 [21211686] [10.1016/j.jacc.2010.06.055](https://doi.org/10.1016/j.jacc.2010.06.055)

APPROACH, 2008:

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. *Am Heart J* 2008;156:1074-9 [19033001]

Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garca-Garca HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation* 2010;121:1176-87 [20194881] [10.1161/CIRCULATIONAHA.109.881003](https://doi.org/10.1161/CIRCULATIONAHA.109.881003)

ADOPT, 2006:

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355:2427-43 [17145742]

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 2008;31:845-51 [18223031]

RECORD, 2009:

Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD Effect of the addition of rosiglitazone to metformin or sulphonylureas versus metformin/sulphonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). *Cardiovasc Diabetol* 2008 Apr 24;7:10 [18435852]

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009 Jun 5; [19501900] [10.1016/S0140-6736\(09\)60953-3](https://doi.org/10.1016/S0140-6736(09)60953-3)

Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;: [20118174] [10.1093/eurheartj/ehp604](https://doi.org/10.1093/eurheartj/ehp604)

4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.